NIDDK's $28M P30 Core Centers RFA: What Academic PIs Should Do Before the June 2027 Deadline

Academic PIs running NIDDK-funded labs have a fresh institutional-center target: RFA-DK-28-112, the NIDDK Disease Research and Translational Core Centers program, posts $28 million across roughly 30 P30 awards with a June 1, 2027 application deadline, according to the grants.gov listing.

That is a rare thing in the NIH portfolio — a center mechanism aimed not at a single lab's next hypothesis but at the shared infrastructure that a whole department's worth of investigators leans on. If your institution already has a critical mass of NIDDK-funded science, this is the grant that pays for the microscopes, the sequencing pipelines, the biostatistics desk, and the pilot money that keeps early-career faculty from stalling out. It is worth understanding early, because the strongest P30 applications are assembled over months, not weeks.

What RFA-DK-28-112 actually funds

The grants.gov opportunity listing is the authoritative record here, and it is worth reading closely because P30 center grants do not behave like R01s. The forecast, posted July 2, 2026 under assistance listing 93.847 (Diabetes, Digestive, and Kidney Diseases Extramural Research), sets total program funding at $28 million and an expected 30 awards. There is no cost-sharing requirement, and eligibility is broad on paper — institutions of higher education, nonprofits, for-profits, state and local governments, and tribal organizations all qualify to apply.

That breadth is misleading, though. The P30 "Disease Research and Translational Core Centers" mechanism is not a general-purpose infrastructure grant. It exists to consolidate and amplify research that NIDDK is already funding at an institution. In practice, a competitive applicant needs an existing base of independent, peer-reviewed research — typically a cluster of NIDDK-supported R01-equivalent awards — that the proposed cores would serve. The center does not fund the underlying research projects. It funds the connective tissue: shared core facilities, a pilot and feasibility program, and an enrichment program that pulls the community together.

Do the arithmetic and the shape of the opportunity comes into focus. Twenty-eight million dollars spread across roughly 30 awards works out to a little under $1 million per center — consistent with the direct-cost ceilings NIDDK has historically attached to its core center grants. This is not transformational money for any one investigator. It is leverage. A well-run core center multiplies the productivity of every funded lab that touches it, which is exactly why NIDDK measures these awards by the research base they support rather than by any single discovery.

Why a shared-core grant matters more than it looks

The instinct among PIs is to chase project grants, because project grants are what tenure committees count. But the economics of a modern NIDDK lab increasingly run through shared infrastructure. Single-cell sequencing, metabolic phenotyping, advanced imaging, gnotobiotic mouse facilities, human islet distribution, biostatistics and bioinformatics support — these are line items no individual R01 can carry, and duplicating them lab-by-lab is ruinous. A P30 core center is the mechanism NIH built to solve that collective-action problem.

The disease areas named in the forecast — cystic fibrosis, diabetes, nutrition and obesity, and liver and digestive disease — map onto NIDDK's long-running family of disease-specific core center programs. Historically these have gone out under separate RFAs: Diabetes Research Centers, Nutrition Obesity Research Centers, Cystic Fibrosis Research and Translation Centers, Silvio O. Conte Digestive Diseases Research Core Centers. RFA-DK-28-112 sits in that lineage, and if you have watched those programs recompete on their five-year cycles, the structure will be familiar: an administrative core, a set of biomedical research cores providing shared services, a pilot and feasibility program that seeds new and early-stage investigators, and an enrichment program of seminars, works-in-progress sessions, and visiting speakers.

The pilot and feasibility program is the part that PIs consistently underweight. For a junior faculty member or an established investigator pivoting into a new disease area, a center pilot award — often $30,000 to $75,000 in direct costs — is frequently the bridge that generates the preliminary data for a first R01. Institutions that win a P30 do not just get cores; they get a renewable internal grant engine that de-risks their own pipeline of future NIDDK applicants. That compounding effect is the real return, and it is why a sub-$1M annual award routinely punches far above its budget line.

The eligibility bar that the forecast does not spell out

Here is where the broad eligibility language on grants.gov can mislead a first-time applicant. The formal list of eligible entities is expansive, but the scientific bar is narrow and specific. NIDDK core centers are built on an existing base of funded research, and the review criteria weigh that base heavily. A center application without a demonstrable cluster of independent, peer-reviewed, disease-relevant funding — and without a group of investigators who will actually use the proposed cores — does not compete, regardless of institutional prestige.

Practically, that means three things for a PI weighing whether to lead an application. First, inventory your institution's NIDDK-relevant funding honestly: how many independent awards, in which disease area, and are the PIs committed to using shared cores? Second, identify the cores that would genuinely add value rather than the ones that sound impressive — reviewers reward cores with a clear user base and a plausible cost-recovery model, and penalize cores that read like wish lists. Third, start the internal politics now. A P30 is an institutional commitment: it requires letters, space, cost-sharing of effort (even without a formal match), and a director with the standing to arbitrate between competing labs. None of that assembles quickly.

The June 1, 2027 due date looks distant from July 2026, but the forecast status is itself a signal. NIDDK posts these opportunities as forecasts precisely so that institutions can begin organizing before the full announcement drops with its final budget caps, letter-of-intent date, and specific review criteria. The gap between a forecast and a due date is not slack — it is the assembly window, and the centers that win are the ones that used it.

What to watch as the forecast converts to a full announcement

Because the listing is still a forecast, several load-bearing details remain unspecified: the award ceiling and floor, the letter-of-intent deadline, and the exact required-core structure for this competition. Those will land in the full RFA. When it does, three numbers deserve immediate attention. The annual direct-cost cap determines how many cores you can realistically staff. The maximum project period — almost certainly five years, in line with the mechanism — sets your planning horizon. And the expected-award count, currently 30, tells you how much competition to price in; a program funding 30 centers nationally across four-plus disease areas is selective but not a lottery.

One more structural note for PIs at institutions that already hold a NIDDK center: recompetition is not a formality. Existing centers apply through the same RFA and are reviewed against new applicants and against their own track record of pilot-award productivity, core usage metrics, and scientific output. If you run a core, the years before a recompete are the years to document usage rigorously. If you are trying to unseat one, the pitch is a stronger, better-integrated research base — not a longer list of instruments.

Your next step

The gap between a forecasted P30 and a fundable application is mostly homework — knowing which of your colleagues' grants form a qualifying research base, and which cores that base would actually pay to use. Start by mapping the live NIDDK-relevant funding landscape in your disease area so you can see where your institution sits. You can search active NIDDK and diabetes, digestive, and kidney disease solicitations on Granted to build that picture and track how the forecast for RFA-DK-28-112 evolves into a full announcement.

For a broader grounding in how center and infrastructure mechanisms differ from project grants — and how to position an institutional application — the Granted blog is the place to start. The PIs who win P30s are rarely the ones with the flashiest single project. They are the ones who understood, early, that the grant rewards a community, and who spent the forecast window building one.